Compare UMH & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UMH | ARDX |
|---|---|---|
| Founded | 1968 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | N/A | 2014 |
| Metric | UMH | ARDX |
|---|---|---|
| Price | $16.10 | $7.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $17.75 | $12.95 |
| AVG Volume (30 Days) | 501.5K | ★ 4.5M |
| Earning Date | 02-25-2026 | 02-19-2026 |
| Dividend Yield | ★ 5.68% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | $256,272,000.00 | ★ $398,234,000.00 |
| Revenue This Year | $10.80 | $22.44 |
| Revenue Next Year | $8.34 | $34.00 |
| P/E Ratio | $201.70 | ★ N/A |
| Revenue Growth | 8.96 | ★ 58.12 |
| 52 Week Low | $13.95 | $3.21 |
| 52 Week High | $19.14 | $8.40 |
| Indicator | UMH | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 56.27 | 51.35 |
| Support Level | $15.71 | $6.92 |
| Resistance Level | $16.06 | $8.02 |
| Average True Range (ATR) | 0.31 | 0.36 |
| MACD | 0.01 | -0.12 |
| Stochastic Oscillator | 84.76 | 23.31 |
UMH Properties Inc together with its subsidiaries is a real estate investment trust. It is engaged in the business of ownership and operation of manufactured home communities - leasing manufactured homesites to residents . The Company also leases manufactured homes to residents and, through its wholly-owned taxable REIT subsidiary, UMH Sales and Finance, Inc. sells and finances the sale of manufactured homes to residents and prospective residents of its communities and for placement on customers' privately-owned land. The company also owns the land, utility connections, streets, lighting, driveways, common area amenities, and other capital improvements. It earns income from lease agreements for their sites and homes, where the company is the lessor.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.